ClinicalTrials.gg
TerminatedNCT00266214Updated Jun 14, 2011

Safety and Efficacy of Lidoderm (Lidocaine Patch 5%) in Treating Moderate to Severe Pain Associated With Carpal Tunnel Syndrome

A Phase 3 interventional study of lidocaine patch 5% in Carpal Tunnel Syndrome, sponsored by Endo Pharmaceuticals. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-06-14.

Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 3, Interventional, and Treatment

Why this study was terminated
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 97 studies in Carpal Tunnel Syndrome with a site in United States — 11 open to participants now, 13 under way, none of them phase 3. Carpal Tunnel Syndrome · United States.

Enrollment
4th of 72
210 · median 50
Started
2005
the only one that year
Phase 3
2 of 97
none open now
Registered
5th of 97
by date
Lead sponsor
2 of 97
Endo Pharmaceuticals

Among the 97 studies in Carpal Tunnel Syndrome with a site in United States, this one is the 4th largest by enrollment of the 72 interventional ones that give a count, is the only one that started in 2005, is one of 2 in phase 3, and was the 5th registered.

Carpal Tunnel Syndrome

589 studies on the registry are indexed under Carpal Tunnel Syndrome; 134 are open to participants now.

Browse Carpal Tunnel Syndrome studies →

Open to participants now

11 of the 97 studies in Carpal Tunnel Syndrome with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 73 Carpal Tunnel Syndrome studies recruiting now, 27 (37%) set no upper age limit and 37 (51%) stop at 75 or younger; 1 takes children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 97 studies in Carpal Tunnel Syndrome with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the analgesic efficacy and safety of the lidocaine patch 5% compared to placebo in patients with moderate to severe pain associated with carpal tunnel syndrome.

Read the detailed description

Patients with carpal tunnel syndrome (CTS)as determined by electrodiagnostic testing and moderate to severe pain will be randomized to receive either the lidocaine patch 5% or placebo patch q24h. The total duration of the double-blind treatment phase of the study will be 8 weeks.

At baseline and at periodic visits to the clinic, patients will perform pain and functionality assessments. Patients with bilateral CTS will identify the "index" wrist (i.e., the more painful wrist), which will subsequently be the wrist used for all efficacy assessments throughout the study.

Treatment Regimen and Route of Administration: Patients will apply one patch (either a lidocaine patch 5% or a matching placebo patch) to the volar aspect of each affected wrist once every 24 hours.

03

Conditions studied

  • Carpal Tunnel Syndrome

Keywords

  • lidocaine patch 5%
  • Lidoderm
  • carpal tunnel syndrome
  • pain
  • nerve compression injury
  • topical analgesic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are males or females 18 years of age or older
  • Have confirmed diagnosis of CTS in one or both wrists. For patients with bilateral CTS, the most painful wrist will be identified as the "index" wrist, and will be the wrist used for all efficacy evaluations.
  • Have clinical symptoms of pain, paresthesia, numbness and/or tingling in the distribution of the median nerve
  • Have positive findings from electrodiagnostic tests using accepted criteria
  • Have classification of the wrist(s) as "classic" or "probable" using the Katz Hand Diagram (Katz and Stirrat, 1990)
  • Have worst daily pain intensity greater than 5 (0-10 scale) on approximately 75% of days over the previous 3 months; this criteria will be assessed at the screening visit only
  • Have a normal 12-lead (ECG) without any abnormalities in heart rate, rhythm, or conduction
  • Have been informed of the nature of the study and provided written

Exclusion criteria

Exclusion Criteria:

  • Have a positive serum pregnancy test (females of only)
  • Have tumors or cysts in the wrist, muscle wasting in the forearm and/or hand, peripheral neuropathy, mononeuropathy multiplex, or hand arthritis
  • Have had previous CTS surgery
  • Have severe CTS as defined by electrodiagnostic findings
  • Have had injections for CTS in the previous 3 months
  • Have used diuretics (except a stable dose for hypertension) or Vitamin B6 or topical treatments for CTS (e.g., ultrasound, iontophoresis, cold laser) in the past 2 weeks
  • Require sleep medications
  • Are using a lidocaine-containing product that cannot be discontinued during the study
  • Have a known sensitivity or allergy to an amide-type local anesthetic agent para-aminobenzoic (PABA) derivatives or local anesthetics
  • Have previously participated in a Lidoderm study
  • Have severe renal insufficiency ( of \<30 mL/min)
  • Have moderate or greater hepatic impairment, including a history of or active hepatitis
  • Have abnormal clinical laboratory test results unless deemed clinically insignificant by the investigator
  • Have current or planned litigation, or who are planning to acquire or are currently receiving Worker's Compensation or Social Security benefits, or who, in the opinion of the investigator, exhibit any evidence of secondary gain (monetary or non-monetary) associated with carpal tunnel syndrome pain.
  • Have a history of alcohol or substance abuse within the last 3 years
  • Have received an drug or product or participated in an investigational drug study within a period of 30 days or 5 half-lives prior to receiving study drug
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
210 participants (actual)

Study arms

  • Experimental
    Lidocaine Patch 5%

    1 patch applied topically to the volar aspect of each affected wrist daily, 2-4 hours before bedtime.

    Drug: lidocaine patch 5%

  • Placebo comparator
    Placebo

    1 patch applied topically to the volar aspect of each affected wrist daily, 2-4 hours before bedtime.

    Drug: lidocaine patch 5%

Interventions

  • 1 patch applied topically to the volar aspect of each affected wrist daily, 2-4 hours before bedtime

    Also known as: Lidoderm

06

What researchers measure

Primary outcomes

  1. Worst daily pain intensity score

    Time frame: Week 8

Secondary outcomes

  1. Average daily pain intensity score

    Time frame: Week 8

  2. Levine CTS Symptom Severity and Functional Status Scales

    Time frame: Week 8

  3. Mean interference with daily activities

    Time frame: Week 8

  4. Intensity of Various Pain Qualities

    Time frame: Week 8

  5. Quality of Sleep

    Time frame: Week 8

  6. Global Assessment of Treatment Satisfaction and Impression of Change

    Time frame: Week 8

07

Study locations

1 site
  • PPD
    Austin, Texas 78704, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2005, a primary completion of Jan 2007 and a completion of Jan 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2005
First posted
Dec 16, 2005
Start
Nov 2005
Primary completionActual
Jan 2007
CompletionActual
Jan 2007
Last update
Jun 14, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00266214
First posted
Dec 16, 2005
Start date
Nov 2005
Primary completion
Jan 2007
Completion
Jan 2007
Last update
Jun 14, 2011

Study contacts

PPD
study director · PPD DEVELOPMENT, LP
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lidoderm

Start the discussion